• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Soligenix, Inc. - Common Stock (NQ: SNGX )

    2.260 -0.090 (-3.83%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 35,452
    Open 2.430
    Bid (Size) 2.190 (3)
    Ask (Size) 2.270 (1)
    Prev. Close 2.350
    Today's Range 2.220 - 2.430
    52wk Range 1.830 - 14.92
    Shares Outstanding 2,509,499
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Soligenix Aims To Push The Boundaries In Treating Rare Diseases
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Soligenix Aims To Push The Boundaries In Treating Rare Diseases
    Via TheNewswire.com

    Performance

    YTD
    -23.13%
    -23.13%
    1 Month
    -9.24%
    -9.24%
    3 Month
    -32.34%
    -32.34%
    6 Month
    -42.35%
    -42.35%
    1 Year
    -80.11%
    -80.11%

    More News

    Read More
    Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
    Via NewMediaWire
    Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
    Via TheNewswire.com
    Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
    Via NewMediaWire
    Exposures COVID-19
    Soligenix Announces Participation at the Spartan Capital Investor Conference
    Via TheNewswire.com
    Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
    Via TheNewswire.com
    Exposures COVID-19
    Soligenix Targets Psoriasis With New Therapy
    Via News Direct
    EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
    Via Benzinga
    Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
    Via News Direct
    EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
    Via Benzinga
    Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
    Via News Direct
    DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
    Via ACCESSWIRE
    Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
    Via ACCESSWIRE
    Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Soligenix Announces Participation at the Spartan Capital Investor Conference
    Via NewMediaWire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    7 Top Stocks Under $10: July 2024 Edition
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.